Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
====================================================================================================================================

* Joao V Alessi
* Biagio Ricciuti
* Elizabeth Jiménez-Aguilar
* Fangxin Hong
* Zihan Wei
* Mizuki Nishino
* Andrew J Plodkowski
* Peter Sawan
* Jia Luo
* Hira Rizvi
* Brett W Carter
* John V Heymach
* Mehmet Altan
* Matthew Hellmann
* Mark Awad